The Week Ahead In Biotech: Jazz Awaits FDA Nod For Sleep Disorder Drug, Earnings Trickle In, ACell IPO

Biotech stocks advanced in the week ended July 17 thanks to positive broader market sentiment, encouraging news flow on the COVID-19 front and fairly positive results reported by pharma giant Johnson & Johnson JNJ.

Equillium Inc EQ was among the biggest gainers of the week after a drug that it licensed from Biocon was granted emergency use authorization in India for treating cytokine release syndrome in COVID-19 patients with moderate to severe acute respiratory distress syndrome.

Moderna Inc MRNA advanced in all five sessions of the week, with detailed interim Phase 1 data publication, positive sell-side commentary and news of inclusion in the Nasdaq 100 Index serving as catalysts.

The following are key catalysts in the unfolding week.

Conferences

Galactosemia Foundation 2020 Virtual Conference, July 17-19

PDUFA Dates

The FDA is set to rule on Jazz Pharmaceuticals PLC's JAZZ NDA for JZP-258, which is being evaluated as a treatment option for cataplexy —excessive daytime sleepiness — in patients 7 and older with narcolepsy.

Earnings

• Biogen Inc BIIB (Wednesday, before the market open)
• Quest Diagnostics Inc DGX (Thursday, before the market open)
• West Pharmaceutical Services Inc. WST (Thursday, before the market open)
• Edwards Lifesciences Corp EW (Thursday, after the close)
• LeMaitre Vascular Inc LMAT (Thursday, after the close)

IPOs

ACell, a regenerative medicines company that develops products designed to facilitate the body's ability to repair and remodel tissue, is planning a 5-million-share IPO at an estimated price range of $14-$16. The company has applied for listing its shares on the Nasdaq under the ticker symbol "ACLL."

IPO Quiet Period Expirations

• Polypid Ltd PYPD
• Akouos Inc AKUS
• Fusion Pharmaceuticals Inc FUSN
• ADiTx Therapeutics Inc ADTX

Related Links:

Researchers Say AbbVie's Tricor Reduced Severity Of COVID-19 Into 'Nothing Worse Than A Common Cold'

4 Ways Biogen's Tecfidera Generic Battle Could Play Out For The Stock